glp 1 in europe UK gives Wegovy GLP-1 pill first European approval Europe Glucagon-like Peptide-1 (GLP-1) Agonists
Description
Patients with longstanding diabetes and established autonomic neuropathy face elevated baseline gastroparesis risk independent of GLP-1 use, making causality attribution particularly challenging in this population
For example, in head-to-head discussions, analysts have noted that Mounjaros weight-loss results slightly outperformed Wegovys in comparable trials
Many struggle with fatigue, nausea, nutrient depletion, and eventual weight regain once therapy stops
Biochem Biophys Res Commun 530(3):494499
